(Q40026048)

English

Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.

scientific article published on 10 January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

author name string

Robert A Ogert

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Lisa Wojcik

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Catherine Buontempo

3

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Lei Ba

4

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Peter Buontempo

5

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Robert Ralston

6

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Julie Strizki

7

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

John A Howe

8

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

language of work or name

0 references

publication date

10 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

number of pages

13

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

373

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

387-399

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Assessing chemokine co-receptor usage in HIV

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

HIV-1 integrase inhibitors: an emerging clinical reality

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

V3: HIV's switch-hitter

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Structure of a V3-containing HIV-1 gp120 core

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

CCR5 interactions with the variable 3 loop of gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

HIV-1 coreceptor usage, transmission, and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Chemokine antagonists as therapeutics: focus on HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.12.009

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2007.12.009

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40026048&oldid=1771975772"